Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Le coin des francophones -- Ignore unavailable to you. Want to Upgrade?

To: Claude Cormier who wrote (11906)	2/1/2000 1:08:00 PM
From: AriKirA	Read Replies (1) \| Respond to of 77509

2 titres pour les traders... IN semble bouger sur le MSE IMM nouvelle out ... possibilite de gap pour demain si les journaux publient des articles sur la nouvelle suivante Immune Network Research Ltd - Immune's AIDS drug candidate shows positive effects Immune Network Research Ltd IMM Shares issued 27,939,465 2000-01-31 close $0.9 Tuesday Feb 1 2000 Mr. Allen Bain reports A study published in the latest issue of the Journal of Immunology and Cell Biology reports that the company's anti-idiotypic antibody 1F7, selectively inhibits cytotoxic T cells activated in HIV-1 infection. Following HIV-1 infection, the number of CD8+ T lymphocytes (CTL) increases substantially. These cells include a cell population, expanded in HIV infection, that targets both infected and uninfected CD4+ lymphocytes. Associated depletion of uninfected CD4+ cells is characteristic of disease progression. Therefore, modulation of the CTL activated in HIV infected individuals may be beneficial. Dr. Michael Grant, a member of Immune Network's scientific advisory board, led this study. Dr. Grant is presently assistant professor of immunology in the faculty of medicine at Memorial University where he is continuing his studies on immune system function and HIV. Dr. Grant is the recipient of a number of research awards and is a national AIDS scholar. Immune Network's commercial director, Ron Kertesz, said: "The results of this recent study indicate that 1F7 selectively inhibits the CTL mediated destruction of uninfected CD4+ cells. This is a very significant finding which further strengthens the potential of this antibody to become an effective AIDS therapeutic. Simplistically put, what we have here is some positive indication that our anti-AIDS drug candidate may help reduce the number of killer T cells that destroy uninfected helper T cells. This is in addition to previous evidence indicating increased antibody production against mutated forms of the virus." WARNING: The company relies upon litigation protection for "forward-looking" statements. (c) Copyright 2000 Canjex Publishing Ltd. canada-stockwatch.com